0153: Galectin 3 for risk stratification in ambulatory heart failure patients

Background Galectin-3 (Gal-3) is an emerging biomarker promising to assess prognosis in various pathophysiological conditions including heart failure (HF). The aim of this work was to investigate the prognosis interest of this marker in ambulatory patients with stable HF. Methods Patients were included in this study in 2010. All patients gave informed consent. Clinical characteristics were registered and biomarkers were assessed. Clinical outcomes were registered regularly by a clinical follow-up or by phone by a dedicated physician. Results 180 patients (mean age 72.5y±12.5y) were included. Left ventricular ejection fraction was 37.1%±14.2%. Median (1st quartile – 3rd quartile) follow-up was 42.3 (12.3-47.1) months. Survival curves were built and data presented as means±SD when normally distributed. Patients who died during follow up had higher Gal-3 levels at baseline. In partial correlation analysis, Gal-3 level was negatively correlated to renal function assessed by CKD-EPI estimated glomerular filtration rate (Spearman’s rho=-0.252, p=0.003) and positively correlated to NT-proBNP (rho=0.367, p Conclusion Galectin-3 provides information regarding risk of death in ambulatory heart failure patients and is tightly correlated to NT-proBNP and renal function.